Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness and paralysis. Effective immunosuppression is the standard of care for relapse prevention. OBJECTIVE: To compare the relapse and treatment failure rates among patients receiv...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Mealy, M, Wingerchuk, D, Palace, J, Greenberg, B, Levy, M
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2014

Gelijkaardige items

Treatment of Neuromyelitis Optica: Review and Recommendations.
door: Kimbrough, D, et al.
Gepubliceerd in: (2012)

Treatment of neuromyelitis optica: Review and recommendations
door: Kimbrough, D, et al.
Gepubliceerd in: (2012)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
door: Tackley, G, et al.
Gepubliceerd in: (2016)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
door: Elsone, L, et al.
Gepubliceerd in: (2012)

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
door: Levy M, et al.
Gepubliceerd in: (2021-08-01)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
door: Palace, J, et al.
Gepubliceerd in: (2010)

Seasonal pattern of variation in neuromyelitis optica relapses
door: Elsone, L, et al.
Gepubliceerd in: (2012)

A practical guide to the treatment of neuromyelitis optica.
door: Palace, J, et al.
Gepubliceerd in: (2012)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
door: Achim Berthele, et al.
Gepubliceerd in: (2023-04-01)

Prognosis of Relapsing Neuromyelitis Optica
door: J Gordon Millichap
Gepubliceerd in: (2003-03-01)

Relapsing neuromyelitis optica spectrum disorder
door: M Lakshmi Lavanya, et al.
Gepubliceerd in: (2021-01-01)

The borderland of neuromyelitis optica.
door: Matthews, L, et al.
Gepubliceerd in: (2009)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
door: Sedani, S, et al.
Gepubliceerd in: (2012)

Racial differences in neuromyelitis optica spectrum disorder
door: Kim, S, et al.
Gepubliceerd in: (2018)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
door: Kitley, J, et al.
Gepubliceerd in: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
door: Kitley, J, et al.
Gepubliceerd in: (2014)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
door: Pittock, S, et al.
Gepubliceerd in: (2019)

Use of mitoxantrone in neuromyelitis optica.
door: Kitley, J, et al.
Gepubliceerd in: (2011)

Treatment strategies for neuromyelitis optica
door: Tzu-Lun Huang, et al.
Gepubliceerd in: (2018-01-01)

Magnetic resonance imaging in neuromyelitis optica.
door: Tackley, G, et al.
Gepubliceerd in: (2014)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
door: Waters, P, et al.
Gepubliceerd in: (2015)

Observation of the efficacy of ofatumumab in the treatment of neuromyelitis optica spectrum disorders
door: ZHANG Rui, et al.
Gepubliceerd in: (2024-06-01)

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
door: Bo Chen, et al.
Gepubliceerd in: (2017-04-01)

Advances in the long-term treatment of neuromyelitis optica spectrum disorder
door: Monique Anderson, et al.
Gepubliceerd in: (2024-01-01)

The evolving clinical spectrum of neuromyelitis optica
door: Viegas, S, et al.
Gepubliceerd in: (2008)

Clinical evaluation of rituximab treatment for neuromyelitis optica
door: M.J. Fernández-Megía, et al.
Gepubliceerd in: (2015-10-01)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
door: Matthews, L, et al.
Gepubliceerd in: (2014)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
door: Fujihara, K, et al.
Gepubliceerd in: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
door: Matthews, L, et al.
Gepubliceerd in: (2013)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
door: Waters, P, et al.
Gepubliceerd in: (2016)

Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder
door: Yi-Hong Liu, et al.
Gepubliceerd in: (2022-09-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
door: Collongues, N, et al.
Gepubliceerd in: (2013)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
door: Akiyuki Uzawa, et al.
Gepubliceerd in: (2011-01-01)

Seasonality of 278 neuromyelitis optica relapses in a Brazilian cohort
door: Denis Bernardi Bichuetti, et al.
Gepubliceerd in: (2015-02-01)

Review: Treatment of neuromyelitis optica: Current debate
door: Tomoko Okamoto, et al.
Gepubliceerd in: (2008-07-01)

Treatment of neuromyelitis optica: an evidence based review
door: Douglas Sato, et al.
Gepubliceerd in: (2012-01-01)

Current and future treatment approaches for neuromyelitis optica
door: Nicolas Collongues, et al.
Gepubliceerd in: (2011-03-01)

A mathematical model of cellular swelling in Neuromyelitis optica
door: Laranjeira, S, et al.
Gepubliceerd in: (2017)

Neuromyelitis Optica
door: Goyal V, et al.
Gepubliceerd in: (2009-10-01)

Neuromyelitis optica
door: Jacob Anu, et al.
Gepubliceerd in: (2007-01-01)